Logo Eidgenössische Technische Hochschule Zürich
Department of Biology​
Logo Eidgenössische Technische Hochschule Zürich

Department
of Biology​

Hematopoietic Stem and Progenitor Cell-State–Cell-Fate Trajectories during the Development of TP53-mutant Leukemia
24–01
Status: Active
Running
Start:
21.09.2020–09.02.2023
Team L-R: Titel Vorname Name , Titel Vorname Name
Hematopoietic Stem and Progenitor Cell-State–Cell-Fate Trajectories during the Development of TP53-mutant Leukemia
Hematopoietic Stem and Progenitor Cell-State–Cell-Fate Trajectories during the Development of TP53-mutant Leukemia
24–01
Hematopoietic Stem and Progenitor Cell-State–Cell-Fate Trajectories during the Development of TP53-mutant Leukemia
Status: Active
Running
Start:
21.09.2020–09.02.2023
Team L-R: Titel Vorname Name , Titel Vorname Name
Institutions
 involved
Institutions
 involved
Our expertise
Schreib einen Titel
Our expertise
Schreib einen Titel
Publications

link =

Prof. Dr. Niko Beerenwinkel
ETH Zürich

Wirkungsorte und Icon-Link als Code am Ende des Textes $

Prof. Dr. Steffen Boettcher
University Hospital Zurich

Wirkungsorte und Icon-Link als Code am Ende des Textes $

Prof. Dr. Niko Beerenwinkel
ETH Zürich

Wirkungsorte und Icon-Link als Code am Ende des Textes $

Prof. Dr. Steffen Boettcher
University Hospital Zurich

Wirkungsorte und Icon-Link als Code am Ende des Textes $

You are currently at project

24–01
21–01
Effector-target cell interactions in engineered immune-therapy against hematologic malignancies
Prof. Dr. Timm Schroeder
ETH Zurich
Prof. Dr. med. Markus G. Manz
University Hospital Zurich

é
21–02
Understanding how clonal hematopoiesis feeds lymphoma
Prof. Dr. med. Andrea Alimonti
ETH Zurich
Prof. Dr. med. Emanuele Zucca
Ente Ospedaliero Cantonale (EOC) / Oncology Institute of Southern Switzerland (IOSI)

é
21–03
Overcoming the challenge of T-cell lymphoma treatment by safe and efficacious anti-​CD30 radioimmunotherapy with β-​particle and ultra-​short range Auger and conversion electron emitting radionuclides
Prof. Dr. Roger Schibli
ETH Zurich
Prof. Dr. med. Urban Novak
Inselspital / University Hospital Bern

é
22–01
Exploring the potential of targeting IL-​21/IL-​21R signaling to eliminate human acute myeloid leukemia stem cells
Prof. Dr. Manfred Kopf
ETH Zurich
Prof. Dr. Carsten Riether
Inselspital & University of Bern

é
22–02
Regulatory T-cells as tumor-​promoting cellular partners and potential therapeutic targets in diffuse large B-​cell lymphoma
Prof. Dr. Nicola Aceto
ETH Zurich
Prof. Dr. Alexandar Tzankov
University Hospital Basel

é
23–01
Harnessing gut microbiome metabolism for personalized treatment of lymphoma and leukemia
Prof. Dr. Nicholas Bokulich
ETH Zurich
Prof. Dr. med. Jörg Halter
University Hospital Basel

é
24–02
 24 – 02
Prof. Dr. Andreas Moor
ETH Zürich
Prof. Dr. med. Thorsten Zenz
Universitätsspital Zürich

é
25–01
Targeting Metabolic Dependencies in MPN HSPCs
Prof. Dr. Nina Cabezas Wallscheid
ETH Zürich
Prof. Dr. Alexandre Theocharides
UZH

é
24–01
Hematopoietic Stem and Progenitor Cell-State–Cell-Fate Trajectories during the Development of TP53-mutant Leukemia
Prof. Dr. Niko Beerenwinkel
ETH Zürich
Prof. Dr. Steffen Boettcher
University Hospital Zurich

é
Max MustermannCEO